Behind The Hype, Crispr Is A Story Of Slow Progress And Acrimony – Seeking Alpha
|
Behind The Hype, Crispr Is A Story Of Slow Progress And Acrimony
Seeking Alpha Some people reading this morning's mainstream press headlines about a Nature paper describing the correction of a germline mutation using Crispr (NASDAQ:CRSP) might be excused for thinking that we are entering a Gattaca-like world of designer babies. Trading Spotlight on Crispr Therapeutics AG (CRSP) Shares Marathon Asset Management Llp Boosted Compania De Minas Buenaventura (BVN) Holding; Crispr Therapeutics AG … |
